Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ICEF 15

Next Previous
Search
Drug Profile

ICEF 15

Alternative Names: aSMDC - Innovacell Biotechnologie GmbH; autologous Skeletal Muscle Derived Cells - Innovacell Biotechnologie GmbH; ICEF-15; NPJ 5007

Latest Information Update: 16 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innovacell Biotechnologie GmbH
  • Developer Innovacell Biotechnologie GmbH; Norgine
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Faecal incontinence

Most Recent Events

  • 01 Aug 2024 Phase-III clinical trials in Faecal Incontinence in Sweden, Japan, United Kingdom, France, Germany, Austria (IM), prior to August 2024 (NCT04976153)
  • 01 Feb 2022 Innovacell AG initiated a phase II trial in fecal incontinence in Austria (EudraCT2021-005399-21)
  • 27 Oct 2021 Phase-III clinical trials in Faecal Incontinence in Czech Republic, Bulgaria, Italy, Poland (IM) (NCT04976153) (EudraCT2021-001376-42)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top